title: The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
abstract: The programmed death-1 (PD-1), a coinhibitory receptor expressed on activated T cells and B cells, is demonstrated to induce an immune-mediated response and play a critical role in tumor initiation and development. The cancer patients harboring PD-1 or PD ligand 1 (PD-L1) protein expression have often a poor prognosis and clinical outcome. Currently, targeting PD-1 pathway as a potential new anticancer strategy is attracting more and more attention in cancer treatment. Several monoclonal antibodies against PD-1 or PD-L1 have been reported to enhance anticancer immune responses and induce tumor cell death. Nonetheless, the precise molecular mechanisms by which PD-1 affects various cancers remain elusive. Moreover, this therapy is not effective for all the cancer patients and only a fraction of patients respond to the antibodies targeting PD-1 or PD-L1, indicating these antibodies may only works in a subset of certain cancers. Thus, understanding the novel function of PD-1 and genetic determinants of response to anti-PD-1 therapy will allow us to develop a more effective and individualized immunotherapeutic strategy for cancer.
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.|Department of Immunology, University of Toronto, Toronto, ON, Canada.
authors: Xinbing
authors: X
authors: Sui
authors: Department of Gastrointestinal Surgery, Nankai Hospital, Nankai District, Tianjin, China.
authors: Junhong
authors: J
authors: Ma
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Weidong
authors: W
authors: Han
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Xian
authors: X
authors: Wang
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.
authors: Yong
authors: Y
authors: Fang
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
authors: Da
authors: D
authors: Li
authors: Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.|Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China.|Department of Immunology, University of Toronto, Toronto, ON, Canada.
authors: Hongming
authors: H
authors: Pan
authors: Department of Immunology, University of Toronto, Toronto, ON, Canada.|Transplantation Institute and Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
authors: Li
authors: L
authors: Zhang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology*; D060890:B7-H1 Antigen / Q000276:immunology*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D061026:Programmed Cell Death 1 Receptor
keywords: PD-1; PD-L1; cancer; checkpoint inhibitor; immunotherapy